US · Healthcare · Biotechnology
EPS came in at -0.94 against a street estimate of -1.04 — a beat of 9.6%.
Analysts rate Celldex Therapeutics Inc a strong buy (14 buy, 1 hold, 0 sell out of 15) with an average price target of $63.07.
| Fund | Stake |
|---|---|
| Wellington Management Company LLP | 12.16% |
| BlackRock Inc | 8.92% |
| Kynam Capital Management, LP | 6.78% |
| T. Rowe Price Associates, Inc. | 5.97% |
| State Street Corp | 4.97% |
| FMR Inc | 4.74% |
| Vanguard Capital Management, LLC | 4.41% |
| Deep Track Capital, LP | 3.74% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 CELLDEX THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Celldex Therapeutics, Inc. (ticker: CLDX, trades on Nasdaq Capital Market) | 2026-09-22 |
| Quarterly report · Q2 2026 CELLDEX THERAPEUTICS, INC. — SUMMARY FOR RETAIL INVESTORS Q2 2026 (Six Months Ended June 30, 2026) --- HEADLINE NUMBERS • Cash & Liquid Assets: $71 | 2026-08-06 |
| Results announced · Q3 2026 CELLDEX THERAPEUTICS - Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $717.6 million as of June 30, 2026 (up from $451.5 million March | 2026-08-06 |
| Board / officer change · Q3 2026 CELLDEX THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial or operational metrics provided in this filing – this is a personnel/g | 2026-07-15 |
| Board / officer change · Q2 2026 CELLDEX THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 25, 2026 • Equity incentive plan shares increased by 3,400 | 2026-06-26 |
| Quarterly report · Q1 2026 CELLDEX THERAPEUTICS, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Cash position: $35.7 million cash + $415.7 million marketable securities = $451.5 mi | 2026-05-07 |
| Results announced · Q2 2026 CELLDEX THERAPEUTICS Q1 2026 SUMMARY HEADLINE NUMBERS • Cash Position: $451.5 million in cash, cash equivalents and marketable securities as of Marc | 2026-05-07 |
| Proxy statement · Q2 2026 CELLDEX THERAPEUTICS, INC. – PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 – Election of Nine Directors: Vote FOR the electio | 2026-04-29 |
Readable in the app.
| Announcement | Date |
|---|---|
| Phase 3 topline data expected Sept/Oct 2026; BLA submission planned 2027 Celldex announced Q2 2026 results with significant progress on its lead drug barzolvolimab and promising early data from a new bispecific candidate CDX-622. Key highlights: (1) Barzolvolimab | 2026-08-06 |
| Raised $345M in financing; multiple 2026 data readouts expected Celldex Therapeutics reported positive Q1 2026 results with major progress on its lead drug barzolvolimab, a mast cell inhibitor targeting chronic urticaria and other inflammatory diseases. | 2026-05-07 |
| Phase 3 enrollment completed ahead of schedule; topline data expected 2026 Celldex Therapeutics announced strong progress on its lead drug barzolvolimab, a treatment for chronic urticaria and related skin conditions. Key highlights: enrollment in two Phase 3 chroni | 2026-02-25 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Celldex Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.